Bio-Rad Laboratories(NYSE) BIO

Bio-Rad makes tools that help scientists study diseases and doctors run medical tests. These products let laboratories identify biological materials like cells and proteins in human samples. The company serves hospitals, universities, and food safety testers around the world.

What Bio-Rad Sells

• Clinical Diagnostics: Test systems, kits, and software used by hospital labs to identify substances in patient tissue, blood, or urine; represented 60% of net sales in 2025.
• Life Science: Instruments and reagents used to separate and quantify biological materials for research and drug production; accounted for 40% of net sales in 2025.
• In Vitro Diagnostics: Specialized tests performed outside the human body to measure medical conditions; these address specific niches within the global testing market.
• Quality Controls: Materials used by clinical laboratories to ensure their diagnostic test results are accurate and reproducible.

Recent Strategic Moves

• Completed restructurings in 2023, 2024, and 2025 to adjust the company's organizational structure.
• Maintained a significant 38% ownership of ordinary shares in Sartorius AG, a laboratory technology provider.
• Invested in companies developing new technologies to expand the existing portfolio of life science and diagnostic products.
• Issued 3.7% Senior Notes due in 2032 to manage long-term debt obligations.

A Specialized Global Presence

The company operates a direct sales model in over 36 countries to maintain deep relationships with research and medical professionals. With over 2,100 patents, its competitive advantage relies on specialized technical skills and an installed base of diagnostic systems that generate recurring revenue.

Key Financial Facts

• Net sales reached $693.2 million in Q4 2025, up 3.9% from Q4 2024.
• Net income rose to $720 million in Q4 2025, up 200.6% year-over-year.
• Free cash flow hit $119.1 million in Q4 2025, up 46.6% from the previous year.
• Operating income was $61.9 million in Q4 2025, up 6.1% year-over-year.
• The fair value of the Sartorius AG investment was $5.67 billion as of December 31, 2025.

The Bottom Line

Bio-Rad has transitioned into a global provider of specialized medical and research tools with a high reliance on recurring sales. Its significant equity position in other industry players and its dual focus on research and clinical testing provide a diversified presence in the healthcare sector.